Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP26A1 | O43174 | 3/20 | 0.38 |
| ▸ | CYP24A1 | Q07973 | 3/20 | 0.37 |
| ▸ | CYP27A1 | Q02318 | 2/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
| ▸ | KDM6B | O15054 | 1/20 | 0.35 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | DHODH | Q02127 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.33 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4433213 | 0.83 | CYP24A1 (0.43) | CYP26A1CYP24A1CYP27A1CYP19A1SMN1; SMN2 | |
| SCHEMBL30646096 | 0.80 | MELK (0.35) | CYP26A1CYP24A1CYP27A1CYP19A1DHODH | |
| SCHEMBL4419499 | 0.79 | CYP19A1 (0.38) | CYP26A1CYP24A1CYP27A1CYP19A1 | |
| SCHEMBL4423354 | 0.75 | NPC1 (0.41) | CYP26A1CYP24A1CYP27A1CYP19A1SMN1; SMN2 | |
| SCHEMBL11643793 | 0.75 | GRM5 (0.45) | DHODHALDH1A1KMT2AL3MBTL1PDE4B | |
| Hydrochloric Acid SCHEMBL4432412 | 0.74 | NPC1 (0.40) | CYP26A1CYP24A1CYP27A1CYP19A1SMN1; SMN2 | |
| SCHEMBL4420235 | 0.74 | CYP24A1 (0.42) | CYP26A1CYP24A1CYP27A1CYP19A1SMN1; SMN2 | |
| SCHEMBL30646115 | 0.73 | CYP26A1 (0.47) | CYP26A1CYP24A1CYP27A1CYP19A1DHODH | |
| SCHEMBL5039087 | 0.72 | GRM5 (0.57) | SMN1; SMN2ALDH1A1KMT2AL3MBTL1 | |
| SCHEMBL30558432 | 0.72 | GRM5 (0.57) | SMN1; SMN2ALDH1A1KMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7598384-B2 | Tetrahydroquinolinones and their use as antagonists of metabotropic glutamate receptors | MERZ PHARMA GMBH & CO. KGAA (DE) | 2009-10-06 | — | — | US | disclosed |
| EP-1723116-A2 | TETRAHYDROQUINOLINONES AND THEIR USE AS ANTAGONISTS OF METABOTROPIC GLUTAMATE RECEPTORS | Merz Pharma GmbH & Co. KGaA (DE) | 2006-11-22 | — | — | EP | disclosed |
| WO-2005082856-A2 | TETRAHYDROQUINOLINONES AND THEIR USE AS ANTAGONISTS OF METABOTROPIC GLUTAMATE RECEPTORS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2005-09-09 | — | — | WO | disclosed |
| US-20050197361-A1 | Specific binding is extremely high; low toxicity; high degree of activity; 2-(5-m-Tolyl-thiazol-2-yl )-7,8-dihydro-6H-quinolin-5-one, acute and/or chronic neurological disorders | MERZ PHARMA GMBH & CO. KGAA (DE) | 2005-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197361-A1 | Specific binding is extremely high; low toxicity; high degree of activity; 2-(5-m-Tolyl-thiazol-2-yl )-7,8-dihydro-6H-quinolin-5-one, acute and/or chronic neurological disorders | GRM5, GRIK5, GRIN2C | CYP26A1 2188/4885CYP24A1 3463/4885CYP27A1 2007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.